基于共识的欧洲成人与儿童特应性湿疹(特应性皮炎)治疗指南:第一部分
本指南为欧洲跨学科共识项目,综合其他指南、系统评价和已发表研究的证据,涵盖特应性湿疹的一般措施、回避策略、润肤剂、沐浴、饮食干预、外用抗炎治疗、光疗和止痒治疗,强调治疗需考虑个体临床差异,不推荐高度标准化的治疗规则。
要点
- 基础治疗以外用保湿和润滑修复屏障功能为主,并回避特定和非特定诱发因素。
- 外用糖皮质激素和钙调神经磷酸酶抑制剂用于发作期管理和长期控制的主动性治疗。
- 外用糖皮质激素仍是主要治疗手段,他克莫司和吡美莫司优选用于敏感皮肤区域和长期使用。
核心结论
- 特应性湿疹的管理必须考虑疾病的个体临床变异性,不推荐高度标准化的治疗规则。
研究设计与样本
- 本指南为欧洲跨学科共识项目,纳入所有相关学科医师及患者,基于其他指南、系统评价和已发表研究的证据制定。
主要发现
- 基础治疗侧重于通过保湿和润滑的外用治疗修复屏障功能,并回避特定和非特定诱发因素。
- 外用抗炎治疗基于糖皮质激素和钙调神经磷酸酶抑制剂,用于发作期管理和长期控制的主动性治疗。
- 外用糖皮质激素仍是主要治疗手段,他克莫司和吡美莫司优选用于敏感皮肤区域和长期使用。
- 外用磷酸二酯酶抑制剂在可用时可作为治疗替代选择。
- 辅助治疗包括紫外线照射,优选UVB 311 nm或UVA1。
关键数值与推荐
- 外用糖皮质激素和钙调神经磷酸酶抑制剂用于发作期管理和长期控制的主动性治疗。
- 他克莫司和吡美莫司优选用于敏感皮肤区域和长期使用。
- 外用磷酸二酯酶抑制剂在可用时可作为治疗替代选择。
- 紫外线照射优选UVB 311 nm或UVA1。
临床怎么用
- 基础治疗使用保湿和润滑的外用治疗修复屏障功能,并回避特定和非特定诱发因素。
- 发作期管理和长期控制使用基于糖皮质激素和钙调神经磷酸酶抑制剂的外用抗炎治疗。
- 敏感皮肤区域和长期使用优选他克莫司和吡美莫司。
- 辅助治疗包括紫外线照射,优选UVB 311 nm或UVA1。
- 瘙痒通过大多数推荐疗法进行靶向治疗,但部分患者可能需要额外的止痒治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This guideline was developed as a joint interdisciplinary European project, including physicians from all relevant disciplines as well as patients. It is a consensus-based guideline, taking available evidence from other guidelines, systematic reviews and published studies into account. This first part of the guideline covers methods, patient perspective, general measures and avoidance strategies, basic emollient treatment and bathing, dietary intervention, topical anti-inflammatory therapy, phototherapy and antipruritic therapy, whereas the second part covers antimicrobial therapy, systemic treatment, allergen-specific immunotherapy, complementary medicine, psychosomatic counselling and educational interventions. Management of AE must consider the individual clinical variability of the disease; highly standardized treatment rules are not recommended. Basic therapy is focused on treatment of disturbed barrier function by hydrating and lubricating topical treatment, besides further avoidance of specific and unspecific provocation factors. Topical anti-inflammatory treatment based on glucocorticosteroids and calcineurin inhibitors is used for flare management and for proactive therapy for long-term control. Topical corticosteroids remain the mainstay of therapy, whereas tacrolimus and pimecrolimus are preferred in sensitive skin areas and for long-term use. Topical phosphodiesterase inhibitors may be a treatment alternative when available. Adjuvant therapy includes UV irradiation, preferably with UVB 311 nm or UVA1. Pruritus is targeted with the majority of the recommended therapies, but some patients may need additional antipruritic therapy. Antimicrobial therapy, systemic anti-inflammatory treatment, immunotherapy, complementary medicine and educational intervention will be addressed in part II of the guideline.
引用
- Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018. PMID: 29676534. doi:10.1111/jdv.14891
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。